Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis

StephenW

J Hepatol. 2012 May 30. [Epub ahead of print]
Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H.
SourceDepartment of Hepatology, Toranomon Hospital, Tokyo, Japan.

AbstractBACKGROUND & AIMS: We determined the antiviral potency and viral resistance rate after 4years of continuous entecavir treatment in patients with chronic hepatitis B (CHB) infection.
METHODS: The cumulative rates of undetectable hepatitis B virus DNA (HBV DNA;<2.6 log(10) copies/ml), hepatitis B e antigen (HBeAg) seronegativity, seroconversion, alanine aminotransferase (ALT) normalization, and entecavir signature mutations were calculated in 474 nucleos(t)ide-naïve CHB patients (HBeAg-positive: 47%) on continuous entecavir treatment for 4years.
RESULTS: Median age was 47years and follow-up period was 2.4years, with 403, 281, 165, and 73 patients followed-up for at least 1, 2, 3, and 4years, respectively. Incremental increases were observed in the rates of undetectable HBV DNA, HBeAg seroclearance and seroconversion, and ALT normalization, reaching 96%, 42%, 38% and 93%, respectively, by the fourth year. In all, 100% and 93% of patients negative and positive for HBeAg, respectively, had undetectable HBV DNA at year 4. Of 165 patients, HBV DNA was detectable in nine patients after 3years. Multivariate analysis identified HBV DNA level (⩽7.6log(10) copies/ml, OR=15.8; 95% CI=43.1-79.9, P=0.001) as an independent predictor of undetectable HBV DNA at year 3. Five patients experienced virological breakthrough including two (0.4%) who developed entecavir-resistance mutations.
CONCLUSIONS: Continuous treatment of nucleos(t)ide-naïve CHB patients with entecavir over 4years was associated with 96% chance of undetectable HBV DNA and only 0.4% chance of emerging entecavir-resistant mutations.

StephenW

J肝胆病杂志。2012五月30日。 [出处提前打印]
长期恩替卡韦治疗核苷连续（T）IDE初治慢性乙肝患者。
小野一，铃木FŸ河村，Sezaki保坂ţ，Akuta列印，小林，中号，铃木Ÿ，斋藤小号，荒濑Ÿ，池田ķ，小林中号，小号Watahiki，ŕ峰田，熊田H。
源

肝病，虎门医院，东京，日本。
抽象
背景与目的：

我们确定了抗病毒效力后4年连续恩替卡韦治疗慢性乙型肝炎（CHB）感染患者和病毒的耐药率。
方法：

累积率不到乙肝病毒DNA（HBV  -  DNA<2.6日志（10）拷贝/ ml），乙型肝炎e抗原（HBeAg）抗体阴性，转阴，谷丙转氨酶（ALT）正常化，恩替卡韦签名突变被计算在474核苷（酸）IDE初治的HBeAg阳性慢性乙型肝炎患者（47％）连续4年恩替卡韦治疗。
结果：

年龄中位数为47年和后续期间2.4年，403，281，165，73例患者随访至少1，2，3，4年，。观察增量增加的HBV DNA检测不到率，HBeAg的血清廓清和血清学转换，ALT正常化，达到96％，42％，38％和93％，分别由第四年。在所有中，100％和93％的患者阳性阴性和HBeAg阳性，分别在4年不到的HBV DNA。 165例，HBV DNA的检出9例后3年。多变量分析确定在3年不到HBV DNA的独立预测HBV DNA水平（⩽7.6log（10）拷贝/ ml，OR=15.8;95％CI=43.1-79.9，P = 0.001）。五名病人经历病毒学突破包括开发恩替卡韦耐药突变（0.4％）。
结论：

核苷（酸）IDE天真超过4年恩替卡韦的慢性乙型肝炎患者的持续治疗与恩替卡韦耐药突变的新兴只有0.4％的几率不到HBV DNA的96％的机会。

咬牙硬挺

希望有比恩替和替诺更好的能去根的，rep 9ac有新消息吗？公司网站说是发布数据了怎么没看到呢

StephenW

回复 咬牙硬挺 的帖子

仍在等待所有ISVHLD的摘要在病毒性肝炎杂志发表.